Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and small-cap biotech stocks a median 8%.
−2Long-term trend
MLYS's Quality Score rose 1 point on Mon, Nov 9, to -4.
Follow MLYS's trial news. Pro members can get an alert when Mineralys Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 29.5% more shares than a year ago |
| Latest filing | 8-K, Nov 4 |
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
2 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -4.2% on average, higher 0 of 4 times.
The company says its cash lasts into 2028 (8-K, Nov 4).
CEO Jon Congleton sold 75,000 shares on Sep 30, under a planned sale. 36 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
MLYS is #199 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 199 |
Share count against a year before: MLYS +29%, VNDA +2.1%, AGIO +2.7%.
Expected to report Thu Feb 11, after the close (in 94 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.64 a share, from $0.52.
“The increase was primarily attributable to the factors impacting the Company’s expenses described above.”
MLYS's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in G&A expenses was primarily due to investments to expand the Company’s operations in preparation for commercialization, including $15.4 million in higher professional fees and $11.4 million in increased personnel-related expenses resulting from headcount growth and increased compensation, as well as $0.9 million of increased other administrative expenses.”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +3.9% | -10.3% | not yet |
| Aug 11, 2026 | -8.1% | -1.0% | -2.6% |
| May 6, 2026 | -3.1% | -2.6% | -10.8% |
RSI 28.7, MACD below signal, below both averages. Not scored.
One insider sold $3M across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: MLYS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
MLYS scores -4 today, which Breakaway calls Poor. It is #199 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and small-cap biotech stocks a median 8%. Shares: 29.5% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MLYS scores -4 today, which Breakaway calls Poor (below zero). That is #199 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MLYS's -4.
One insider sold $3M across 1 filing in the last 6 months. No open-market buys on record. The newest is Brian Taylor Slingsby, Director, who sold $3M on Sep 22.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.